Zharikov A Iu, Zverev Ia F, Briukhanov V M, Lampatov V V
Eksp Klin Farmakol. 2012;75(3):14-7.
Experiments performed on 23 male rats, were divided into 2 groups. Animals in the control received group 1% solution of ethylene glycol (EG) as a drink during 6 weeks. In the test group, EG was also introduced for 6 weeks, and meloxicam was administered in a dose of 2.5 mg/kg from the 4th week. Every 7 days, daily urine was analyzed for the concentrations of oxalate, phosphate, and calcium and for the activity of urothelium injury marker enzymes includng lactate dehydrogenase (LDH), gamma-glutamyl transferase (GGT), and N-acetyl-beta-D-glucose aminidase (NAG). In addition, sections of the rats kidney were used to detect calcium deposits by histochemical Van Koss method. The treatment of experimental nephrolithiasis by meloxicame led to simplification of pathology, as indicated by a significant reduction in the urine oxalate and calcium concentrations and a pronounced decrease in the activity of all marker enzymes (LDH, GGT, NAG).This was confirmed by morphological studies, which detected very significant reduction in both number and size of calcium deposits.
对23只雄性大鼠进行实验，将其分为2组。对照组动物在6周内饮用1%的乙二醇（EG）溶液作为饮品。在实验组中，EG同样饮用6周，从第4周开始以2.5毫克/千克的剂量给予美洛昔康。每隔7天，对每日尿液进行分析，检测草酸盐、磷酸盐和钙的浓度以及尿路上皮损伤标记酶的活性，包括乳酸脱氢酶（LDH）、γ-谷氨酰转移酶（GGT）和N-乙酰-β-D-葡萄糖氨基酶（NAG）。此外，采用组织化学范科萨法，利用大鼠肾脏切片检测钙沉积。美洛昔康治疗实验性肾结石导致病理情况简化，表现为尿草酸盐和钙浓度显著降低，以及所有标记酶（LDH、GGT、NAG）的活性明显下降。形态学研究证实了这一点，该研究检测到钙沉积的数量和大小均显著减少。
